Latest Commercialisation News

HyTerra Limited has unveiled a comprehensive strategic plan to commercialise its Nemaha Project in Kansas, backed by new leadership and a key US technology partnership. The company is advancing towards production testing in 2026 amid promising hydrogen and helium discoveries.

Zeotech Limited has made significant strides in advancing its Toondoon Kaolin Project mining readiness and secured key partnerships to commercialise its AusPozz™ metakaolin product, validated by independent testing.

Imagion Biosystems has completed manufacturing its MagSense® HER2 imaging agent and is preparing for a key FDA submission, while appointing a new president to lead its US operations.

Alpha HPA Limited has raised A$225 million in a fully underwritten placement to fund the commercialisation of Stage 2 of its High Purity Alumina project, with strong backing from the National Reconstruction Fund Corporation. This capital injection positions the company to become the world’s largest single-site HPA manufacturer, supporting critical semiconductor supply chains.

BrainChip Holdings has bolstered its financial position with a A$35 million capital raise and commenced volume production of its AKD1500 neuromorphic AI chip, while deepening its strategic partnership with Parsons’ defence arm.

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

Bass Oil Limited reported a 7.9% rise in quarterly oil sales revenue and a 7.4% increase in production, alongside a pivotal gas sales agreement with Origin Energy for the Vanessa gas field, pending regulatory approval.

Control Bionics has secured a two-year US distribution agreement with AAC leader PRC-Saltillo to broaden access to its NeuroNode technology, enhancing communication options for users with complex needs.

Archer Materials has made significant strides in its quantum computing and medical diagnostics programs, including improved carbon qubit readout and clinical-standard silicon biochips, while securing key partnerships and maintaining a strong cash position.

Biotron Limited has completed the acquisition of Sedarex Limited alongside a $2.5 million capital raising, while its lead Hepatitis B drug candidate BIT-HBV001 shows promising preclinical results outperforming current treatments.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.

CurveBeam AI reported steady device orders alongside a $4 million milestone payment from its China commercialisation deal, while progressing FDA clearance and robotic surgery system validation.